BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc.
FDA approves drug for the treatment of both irritable bowel syndrome with constipation (ibs-c) and chronic idiopathic constipation in adults On August 30, 2012 LINZESS™ (linaclotide) [pronounced ...
Linzess (linaclotide) is a prescription medication approved by the Food and Drug Administration (FDA) to treat certain types of constipation. Most Medicare Part D plans provide coverage for the drug ...
Findings showed 30% of patients taking linaclotide 145mcg achieved the primary endpoint of combined responder. The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the ...
The FINANCIAL — Astellas Pharma Inc. announced that it launched a guanylate cyclase-C (GC-C) receptor agonist, LINZESS Tablets for irritable bowel syndrome with constipation) (“IBS-C”) in Japan on ...
– The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results